Seek Labs Unveils BioSeeker™
June 12, 2025
SALT LAKE CITY, UT, June 10, 2025 (Business Wire) – Seek Labs—a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics—today announced BioSeeker™, a next-generation AI discovery engine redefining how the world identifies and treats disease. It powers Seek Labs’ proprietary Programmable Target Ablation Platform (PTAP), a CRISPR-based system engineered to target and cleave exact genetic sequences required for pathogens to replicate, spread, and cause disease, unlike traditional therapeutic approaches—vaccines, small molecule antivirals, or biological therapies—that attempt to slow, block, or redirect pathogens. BioSeeker rapidly identifies the highest-potential target sites, integrating real-world genomic datasets and proprietary data with powerful computational methods and bioengineering design tools.
“This is the moment where the digital tide of AI converges with scaled datasets and our collective ingenuity to deliver meaningful, precise solutions to combat diseases,” said Alison O’Mahony, VP of Pharmaceutical Research at Seek Labs. “BioSeeker allows us to go from target sequence to CRISPR vector to development candidate in weeks—not years. This not only has the potential to radically accelerate timelines and reduce development costs but improve efficacy and safety by precisely targeting the root cause of disease.”
BREAKING THE BOTTLENECK IN DRUG DISCOVERY
Traditional drug discovery is slow, reactive, and often ineffective against rapidly evolving pathogenic threats. Identifying a viable therapeutic target alone can take years of manual execution and analysis, followed by expensive wet-lab screening in limited contexts with high failure rates. BioSeeker changes that. Using an AI-powered, target-first approach, BioSeeker automates the identification and prioritization of target sites in hours, delivering a constantly expanding portfolio of actionable genetic vulnerabilities across the world’s most dangerous pathogens. These include respiratory viruses, hemorrhagic fevers, and neglected tropical diseases, where current treatments often fall short of meeting the critical and urgent global needs.
The result: programmable, modular, and multiplexed CRISPR-based pan-targeting therapeutics that are being developed to respond rapidly to emerging threats. This process is engineered to minimize off-target effects, with the goal of improving safety and enhancing efficacy by directly disrupting replication pathways to reduce disease and facilitate recovery.
“BioSeeker is not just a discovery tool; it’s an engine for programmable and precise solutions,” said Jared Bauer, CEO of Seek Labs. “This is how we close the gap between global threats and effective response. BioSeeker has already mapped dozens of high-impact targets, and we’re just getting started.”
THE BEGINNING OF A GLOBAL CAMPAIGN
Seek Labs is utilizing BioSeeker to construct a Global Therapeutic Atlas—a living, adaptive map of targetable sequences across zoonotic, pandemic, and drug-resistant diseases. Today’s announcement marks the launch of a multi-month global campaign to unveil BioSeeker’s expanding library of high-priority pathogen targets. Each spotlighted disease will showcase new opportunities for programmable CRISPR intervention.
BioSeeker can also support the design and development of alternative genetic therapies such as siRNA and ASO therapies. Seek Labs is actively engaging partners across biopharma, global health NGOs, and government agencies to accelerate the development of these next-generation interventions.
ACCELERATING DIAGNOSTICS WITH BIOSEEKER AND SEEKIT™
In addition to powering therapeutic development, BioSeeker is being used to accelerate diagnostic innovation through its integration with Seek Labs’ point of care molecular diagnostic system SeekIt™. The process of developing new diagnostic tests—particularly the design of primers and probes—can be time-consuming and resource-intensive. BioSeeker shortens this timeline by identifying pathogen-specific molecular signatures that inform rapid assay design. This allows Seek Labs to more quickly deliver field-ready, point-of-care tests on SeekIt for high-impact diseases.
ABOUT SEEK LABS
At Seek Labs, we don’t wait for change—we build it. We’re seeking the breakthroughs the world can’t wait for by developing programmable “seek and destroy” therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. Powered by our AI discovery engine, BioSeeker™, these platforms form a full-stack development engine—from target discovery to real-world deployment—designed to accelerate innovation and impact across global health.
Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah’s collaborative life sciences ecosystem. Together with our partners, we’re building faster, smarter solutions for the world’s most urgent health challenges.
Recent News
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
- Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
- BlueWind Medical Announces Humana Coverage of Revi® for Urgency Urinary Incontinence, Expanding Access to Millions of Patients
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America’s Healthcare Resilience
